87626-41-3

Usage

Uses

Used in Pharmaceutical Industry:
4-(PYRIDIN-3-YLOXY)BENZALDEHYDE is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs and medicinal compounds. Its unique structure allows it to be a key component in creating molecules with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(PYRIDIN-3-YLOXY)BENZALDEHYDE is utilized as an intermediate in the production of agrochemicals, playing a role in the synthesis of compounds that can enhance crop protection and management.
Used in Organic Synthesis:
4-(PYRIDIN-3-YLOXY)BENZALDEHYDE is employed as a reagent in organic synthesis, where it facilitates various chemical reactions due to its reactive aldehyde group and the presence of the pyridine ring, enabling the creation of a wide array of organic compounds.
Used in Production of Functional Materials:
As a building block, 4-(PYRIDIN-3-YLOXY)BENZALDEHYDE is used in the production of various functional materials, capitalizing on its structural attributes to create materials with specific properties for use in different applications, such as in sensors, catalysts, or other advanced technologies.

Upstream product

• 109-00-2 3-HYDROXYPYRIDINE 
• 459-57-4 4-fluorobenzaldehyde 
• 626-55-1 3-Bromopyridine 
• 123-08-0 4-hydroxy-benzaldehyde 

Downstream Products

• 936343-69-0 3-(4-((E)-2-nitro-vinyl)-phenoxy)-pyridine 
• 1231191-85-7 4-(pyridine-3-yloxy)ethynylbenzene 
• 50596-34-4 (4-(pyridin-2-ylmethoxy)-phenyl)-methanol 
• 437383-99-8 4-(pyridin-3-yloxy)benzoic acid 
• 516481-13-3 2-[4-(3-Pyridyloxy)-phenyl]-1H-benzoimidazole-5-carboxylic Acid Amide 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS

The present disclosure relates generally to compounds useful in treatment of conditions associated with mutant isocitrate dehydrogenase (mt-IDH), particularly mutant IDH1 enzymes. Specifically, the present invention discloses compound of formula (IA), which exhibits inhibitory activity against mutant IDH1 enzymes. Method of treating conditions associated with excessive activity of mutant IDH1 enzymes with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.

Heterocycles substituted pyridine derivatives and antifungal agent containing thereof

An object of the present invention is to provide an antifungal agent which has excellent antifungal effects and is superior in terms of its physical properties, safety and metabolic stability. According to the present invention, there is disclosed a compound represented by the following formula (I), or a salt thereof: wherein R1 represents a hydrogen atom, a halogen atom, an amino group, a C1-6 alkyl group, a C1-6 alkoxy group or a C1-6 alkoxy C1-6 alkyl group; R2 represents a hydrogen atom, a C1-6 alkyl group, an amino group or a di C1-6 alkylamino group; one of X and Y is a nitrogen atom while the other is a nitrogen atom or an oxygen atom; ring A represents a 5- or 6-member heteroaryl ring or a benzene ring which may have a halogen atom, or 1 or 2 C1-6 alkyl groups; Z represents a single bond, a methylene group, an ethylene group, an oxygen atom, a sulfur atom, —CH2O—, —OCH2—, —NH—, —CH2NH—, —NHCH2—, —CH2S—, or —SCH2—; R3 represents a hydrogen atom, a halogen atom, a C1-6 alkyl group, a C3-8 cycloalkyl group, a C6-10 aryl group, a 5- or 6-member heteroaryl group, or 5- or 6-member non-aromatic heterocyclic group which may have 1 or 2 substituents; and R4 represents a hydrogen atom or a halogen atom.

SUBSTITUTED CARBOXYLIC ACID DERIVATIVES

The invention provides novel substituted carboxylic acid derivatives that bind to receptor as ligands of human peroxisome proliferator-activated receptor (PPAR) to activate it and exhibit potent triglyceride-lowering action, cholesterol-lowering action an

Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof

This invention is related to carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones represented by Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein: Y is oxygen or sulfur; R1, R21, R22 and R23 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl; or R22 and R23, together with the N, form a heterocycle; A1 and A2 are independently aryl, heteroaryl, saturated or partially unsaturated carbocycle or saturated or partially unsaturated heterocycle, any of which is optionally substituted; X is one or O, S, NR24, CR25R26, C(O), NR24C(O), C(O)NR24, SO, SO2 or a covalent bond; where R24, R25 and R26 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl. The invention also is directed to the use of carbocycle and heterocycle substituted semicarbazones and thiosemicarbazones for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), for the treatment and prevention of otoneurotoxicity and eye diseases involving glutamate toxicity and for the treatment, prevention or amelioration of pain, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy and urinary incontinence.

Certain pyridyloxy-or-thio-phenyl propenoic acid derivatives

Novel pyridine compounds and the pharmaceutically acceptable salts thereof having a specific inhibitory activity on thromboxane A2 biosynthesis in mammals useful for prevention and treatment of various disorders caused by thromboxane A2/s